NCT05918913 2025-09-05Expanded Access Program for RevumenibSyndax PharmaceuticalsNo longer available1 FDA
NCT03114228 2019-10-15An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)NovartisNo longer available